Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of SoftOx Inhalation Solution in Healthy Subjects
NCT05188638Phase 1Completed
- Sponsor
- SoftOx Solutions
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hypochlorous acid in respiratory tract infection (RTI) and ventilator-associated pneumonia (VAP) (7 arms), sponsored by SoftOx Solutions. Primary endpoints: Occurrence of adverse events, Severity of adverse events and 3 more. Started Oct 2021; status: completed.
02
Drugs
hypochlorous acid
03
Conditions
respiratory tract infection (RTI)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT05188638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05188638.